Cargando…
Gut microbiota in SLE: from animal models to clinical evidence and pharmacological perspectives
Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease driven by complex interactions between genetics and environmental factors. SLE is characterised by breaking self-immune tolerance and autoantibody production that triggers inflammation and damage of multiple organs. Given the...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950977/ https://www.ncbi.nlm.nih.gov/pubmed/36813473 http://dx.doi.org/10.1136/lupus-2022-000776 |
_version_ | 1784893291242717184 |
---|---|
author | Toumi, Eya Mezouar, Soraya Plauzolles, Anne Chiche, Laurent Bardin, Nathalie Halfon, Philippe Mege, Jean Louis |
author_facet | Toumi, Eya Mezouar, Soraya Plauzolles, Anne Chiche, Laurent Bardin, Nathalie Halfon, Philippe Mege, Jean Louis |
author_sort | Toumi, Eya |
collection | PubMed |
description | Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease driven by complex interactions between genetics and environmental factors. SLE is characterised by breaking self-immune tolerance and autoantibody production that triggers inflammation and damage of multiple organs. Given the highly heterogeneous nature of SLE, the treatments currently used are still not satisfactory with considerable side effects, and the development of new therapies is a major health issue for better patient management. In this context, mouse models significantly contribute to our knowledge of the pathogenesis of SLE and are an invaluable tool for testing novel therapeutic targets. Here, we discuss the role of the most used SLE mouse models and their contribution to therapeutic improvement. Considering the complexity of developing targeted therapies for SLE, adjuvant therapies are also increasingly proposed. Indeed, murine and human studies have recently revealed that gut microbiota is a potential target and holds great promises for successful new SLE therapies. However, the mechanisms of gut microbiota dysbiosis in SLE remain unclear to date. In this review, we propose an inventory of existing studies investigating the relationship between gut microbiota dysbiosis and SLE to establish microbiome signature that may serve as a potential biomarker of the disease and its severity as well as a new potential therapy target. This approach may open new possibilities for early diagnosis, prevention and therapeutic perspectives of SLE based on gut microbiome. |
format | Online Article Text |
id | pubmed-9950977 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-99509772023-02-25 Gut microbiota in SLE: from animal models to clinical evidence and pharmacological perspectives Toumi, Eya Mezouar, Soraya Plauzolles, Anne Chiche, Laurent Bardin, Nathalie Halfon, Philippe Mege, Jean Louis Lupus Sci Med Review Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease driven by complex interactions between genetics and environmental factors. SLE is characterised by breaking self-immune tolerance and autoantibody production that triggers inflammation and damage of multiple organs. Given the highly heterogeneous nature of SLE, the treatments currently used are still not satisfactory with considerable side effects, and the development of new therapies is a major health issue for better patient management. In this context, mouse models significantly contribute to our knowledge of the pathogenesis of SLE and are an invaluable tool for testing novel therapeutic targets. Here, we discuss the role of the most used SLE mouse models and their contribution to therapeutic improvement. Considering the complexity of developing targeted therapies for SLE, adjuvant therapies are also increasingly proposed. Indeed, murine and human studies have recently revealed that gut microbiota is a potential target and holds great promises for successful new SLE therapies. However, the mechanisms of gut microbiota dysbiosis in SLE remain unclear to date. In this review, we propose an inventory of existing studies investigating the relationship between gut microbiota dysbiosis and SLE to establish microbiome signature that may serve as a potential biomarker of the disease and its severity as well as a new potential therapy target. This approach may open new possibilities for early diagnosis, prevention and therapeutic perspectives of SLE based on gut microbiome. BMJ Publishing Group 2023-02-22 /pmc/articles/PMC9950977/ /pubmed/36813473 http://dx.doi.org/10.1136/lupus-2022-000776 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Toumi, Eya Mezouar, Soraya Plauzolles, Anne Chiche, Laurent Bardin, Nathalie Halfon, Philippe Mege, Jean Louis Gut microbiota in SLE: from animal models to clinical evidence and pharmacological perspectives |
title | Gut microbiota in SLE: from animal models to clinical evidence and pharmacological perspectives |
title_full | Gut microbiota in SLE: from animal models to clinical evidence and pharmacological perspectives |
title_fullStr | Gut microbiota in SLE: from animal models to clinical evidence and pharmacological perspectives |
title_full_unstemmed | Gut microbiota in SLE: from animal models to clinical evidence and pharmacological perspectives |
title_short | Gut microbiota in SLE: from animal models to clinical evidence and pharmacological perspectives |
title_sort | gut microbiota in sle: from animal models to clinical evidence and pharmacological perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950977/ https://www.ncbi.nlm.nih.gov/pubmed/36813473 http://dx.doi.org/10.1136/lupus-2022-000776 |
work_keys_str_mv | AT toumieya gutmicrobiotainslefromanimalmodelstoclinicalevidenceandpharmacologicalperspectives AT mezouarsoraya gutmicrobiotainslefromanimalmodelstoclinicalevidenceandpharmacologicalperspectives AT plauzollesanne gutmicrobiotainslefromanimalmodelstoclinicalevidenceandpharmacologicalperspectives AT chichelaurent gutmicrobiotainslefromanimalmodelstoclinicalevidenceandpharmacologicalperspectives AT bardinnathalie gutmicrobiotainslefromanimalmodelstoclinicalevidenceandpharmacologicalperspectives AT halfonphilippe gutmicrobiotainslefromanimalmodelstoclinicalevidenceandpharmacologicalperspectives AT megejeanlouis gutmicrobiotainslefromanimalmodelstoclinicalevidenceandpharmacologicalperspectives |